Biosysen Limited (HKG:1355)
Hong Kong · Delayed Price · Currency is HKD 0.1750
+0.0050 (2.94%)
Sep 14, 2026, 1:03 PM HKT
Biosysen Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 50.95 | 51.31 | 40.68 | 67.66 | 63 | 70.56 | |
Revenue Growth | 8.34% | 26.11% | -39.87% | 7.40% | -10.72% | 39.24% |
Cost of Revenue | 42.22 | 36.87 | 19.78 | 22.31 | 26.09 | 25.07 |
Gross Profit | 8.73 | 14.43 | 20.9 | 45.35 | 36.91 | 45.5 |
Selling, General & Admin | 2.65 | 2.65 | 0.13 | - | - | - |
Other Operating Expenses | 27.41 | 28.75 | 8.82 | 10.88 | 12.72 | 10.61 |
Operating Expenses | 42.5 | 46.61 | 19.27 | 54.62 | 43.58 | 40.72 |
Operating Income | -33.77 | -32.18 | 1.63 | -9.26 | -6.67 | 4.77 |
Interest Expense | -4.36 | -4.88 | -5.86 | -5.77 | -7.37 | -8.08 |
Interest & Investment Income | 0 | 0 | 0.01 | 0 | 0.01 | 0.03 |
Earnings From Equity Investments | -1.11 | - | - | - | - | - |
Other Non Operating Income (Expenses) | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
EBT Excluding Unusual Items | -39.27 | -37.08 | -4.24 | -15.05 | -14.05 | -3.3 |
Impairment of Goodwill | - | - | - | -1.86 | - | - |
Gain (Loss) on Sale of Investments | - | - | -2.01 | -1.86 | 1.42 | 2.75 |
Gain (Loss) on Sale of Assets | -0.07 | - | - | - | - | - |
Asset Writedown | -4.33 | -10.22 | -30.82 | -39.9 | - | - |
Other Unusual Items | 65.78 | 1.92 | - | - | -3.48 | 0.4 |
Pretax Income | 22.12 | -45.38 | -37.08 | -58.67 | -16.1 | -0.15 |
Income Tax Expense | - | - | 2.69 | 3.1 | 1.54 | 3.87 |
Earnings From Continuing Operations | 22.12 | -45.38 | -39.76 | -61.77 | -17.65 | -4.02 |
Minority Interest in Earnings | -31.02 | 1.85 | 18.64 | 23.59 | 9.85 | 8.99 |
Net Income | -8.9 | -43.53 | -21.12 | -38.18 | -7.79 | 4.98 |
Net Income to Common | -8.9 | -43.53 | -21.12 | -38.18 | -7.79 | 4.98 |
Net Income Growth | - | - | - | - | - | 141.25% |
Shares Outstanding (Basic) | 1,154 | 965 | 564 | 448 | 448 | 448 |
Shares Outstanding (Diluted) | 1,154 | 965 | 564 | 448 | 448 | 448 |
Shares Change | 54.36% | 71.06% | 25.81% | - | - | - |
EPS (Basic) | -0.01 | -0.05 | -0.04 | -0.09 | -0.02 | 0.01 |
EPS (Diluted) | -0.01 | -0.05 | -0.04 | -0.09 | -0.02 | 0.01 |
EPS Growth | - | - | - | - | - | 141.34% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -11.5 | -49.61 | 24.01 | 34.51 | 6.41 | 14.06 |
Free Cash Flow Per Share | -0.01 | -0.05 | 0.04 | 0.08 | 0.01 | 0.03 |
Gross Margin | 17.14% | 28.13% | 51.38% | 67.03% | 58.58% | 64.48% |
Operating Margin | -66.29% | -62.72% | 4.01% | -13.69% | -10.58% | 6.77% |
Profit Margin | -17.47% | -84.85% | -51.91% | -56.43% | -12.37% | 7.05% |
Free Cash Flow Margin | -22.58% | -96.69% | 59.02% | 51.01% | 10.17% | 19.92% |
EBITDA | -25.92 | -25.84 | 9.18 | -0.42 | 2.69 | 12.93 |
EBITDA Margin | -50.88% | -50.36% | 22.56% | -0.61% | 4.28% | 18.33% |
D&A For EBITDA | 7.85 | 6.34 | 7.55 | 8.85 | 9.36 | 8.16 |
EBIT | -33.77 | -32.18 | 1.63 | -9.26 | -6.67 | 4.77 |
EBIT Margin | -66.29% | -62.72% | 4.01% | -13.69% | -10.58% | 6.77% |